estrogen-receptor positive breast cancer
estrogen-receptor positive breast cancer
Explore linked clinical trials. Standard reference: MONDO:000651223 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs. | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, estrogen-receptor positive breast cancer, neoplasm, skin disorder | Recruiting | Phase 1 / Phase 2 | 2026-10-06 | NCT06590857 | |
| Evaluation of Adherence to Cell Cycle Inhibitors Used as Adjuvant Therapy in Patients With Localized Breast Cancer at High Risk of Recurrence. | Neoplasms by Site, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, estrogen-receptor positive breast cancer, neoplasm, skin disorder | Recruiting | Not stated | 2026-10-02 | NCT07443774 | |
| A Study on Adding Precisely Targeted Radiation Therapy (Stereotactic Body Radiation Therapy) to the Usual Treatment Approach (Drug Therapy) in People With Breast Cancer | Neoplasms by Site, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, estrogen-receptor positive breast cancer, neoplasm, skin disorder | Recruiting | Phase 2 | 2026-10-02 | NCT05534438 | |
| Circulating Tumor DNA | estrogen-receptor positive breast cancer | Recruiting | Phase 2 | 2026-09-21 | NCT06923527 | |
| PAveMenT: Palbociclib and Avelumab in Metastatic AR+ Triple Negative Breast Cancer | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, estrogen-receptor positive breast cancer, neoplasm, skin disorder, triple-negative breast carcinoma | Active, not recruiting | Phase 1 | 2026-08-21 | NCT04360941 | |
| 4FMFES-PET Imaging of ER+ Advanced Breast Cancers | estrogen-receptor positive breast cancer | Recruiting | Phase 2 | 2026-07-10 | NCT04824014 | |
| A Study of the Impact of Endocrine Therapy on Surgical Outcomes in People With Lobular Breast Cancer | Carcinoma, Lobular, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Ductal, Lobular, and Medullary, Skin and Connective Tissue Diseases, adenocarcinoma, breast cancer, breast disorder, breast lobular carcinoma, breast neoplasm, carcinoma, epithelial neoplasm, estrogen-receptor positive breast cancer, neoplasm, skin disorder | Recruiting | Phase 2 | 2026-06-04 | NCT07483307 | |
| Breast Cancer Evolution During Neoadjuvant Systemic Therapy | Neoplasms by Site, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, estrogen-receptor positive breast cancer, neoplasm, skin disorder, triple-negative breast carcinoma | Recruiting | Not stated | 2026-04-16 | NCT06681064 | |
| Fulvestrant, Ipatasertib and CDK4/6 Inhibition in Metastatic ER+/HER2- Breast Cancer Patients Without ctDNA Suppression | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, estrogen-receptor positive breast cancer, neoplasm, skin disorder | Active, not recruiting | Phase 2 | 2026-04-14 | NCT04920708 | |
| A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies | Adnexal Diseases, Carcinoma, Ovarian Epithelial, Digestive System Diseases, Digestive System Neoplasms, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Male Urogenital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Skin and Connective Tissue Diseases, Urogenital Diseases, Urogenital Neoplasms, breast cancer, breast disorder, breast neoplasm, carcinoma, colonic disorder, colorectal cancer, colorectal neoplasm, digestive system disorder, digestive system neoplasm, endocrine system disorder, endometrium neoplasm, epithelial neoplasm, estrogen-receptor positive breast cancer, female reproductive system disorder, female reproductive system neoplasm, gastric cancer, gastric neoplasm, gonadal disorder, intestinal disorder, male reproductive organ cancer, male reproductive system disorder, malignant endocrine neoplasm, neoplasm, ovarian cancer, ovarian disorder, prostate cancer, prostate disorder, rectal disorder, skin disorder, stomach disorder, uterine disorder | Recruiting | Phase 1 / Phase 2 | 2026-03-27 | NCT06395519 | |
| Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, estrogen-receptor positive breast cancer, neoplasm, skin disorder | Active, not recruiting | Phase 3 | 2026-02-12 | NCT02947685 | |
| REVIVE: Replens Versus Intra-Vaginal Estrogen for the Treatment of Vaginal Dryness on Aromatase Inhibitor Therapy | Neoplasms by Site, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, estrogen-receptor positive breast cancer, neoplasm, skin disorder | Active, not recruiting | Phase 2 | 2026-01-28 | NCT01984138 | |
| JAB-2485 Activity in Adult Patients With Advanced Solid Tumors | Neoplasms by Site, Skin and Connective Tissue Diseases, Thoracic Neoplasms, breast disorder, breast neoplasm, bronchial neoplasm, bronchogenic carcinoma, estrogen-receptor positive breast cancer, lung disorder, lung neoplasm, neoplasm, respiratory system disorder, respiratory tract neoplasm, skin disorder, small cell lung carcinoma, triple-negative breast carcinoma | Recruiting | Phase 1 / Phase 2 | 2026-01-09 | NCT05490472 | |
| A Phase Ib/II Study to Evaluate Multiple Combination Therapies of FWD1802 in Patients With ER+/HER2- BC | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, estrogen-receptor positive breast cancer, neoplasm, skin disorder | Recruiting | Phase 1 / Phase 2 | 2026-01-07 | NCT07002177 | |
| Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumor, Including a Cohort Expansion in Esophageal Cancer. | Adnexal Diseases, Digestive System Diseases, Digestive System Neoplasms, Esophageal Neoplasms, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Head and Neck Neoplasms, Liver Neoplasms, Male Urogenital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Skin and Connective Tissue Diseases, Urogenital Diseases, Urogenital Neoplasms, adenocarcinoma, adenoma, benign urinary system neoplasm, breast disorder, breast neoplasm, carcinoma, cervical squamous cell carcinoma, digestive system disorder, digestive system neoplasm, endocrine system disorder, endometrium neoplasm, epithelial neoplasm, esophageal adenocarcinoma, esophageal cancer, esophageal disorder, esophageal squamous cell carcinoma, estrogen-receptor positive breast cancer, female reproductive system disorder, female reproductive system neoplasm, gastroesophageal cancer, gonadal disorder, head and neck squamous cell carcinoma, hepatocellular carcinoma, kidney cancer, kidney disorder, liver disorder, male reproductive organ cancer, male reproductive system disorder, malignant endocrine neoplasm, melanocytic neoplasm, melanoma, mesothelial neoplasm, mesothelioma, neoplasm, neuroendocrine neoplasm, non-small cell lung carcinoma, ovarian cancer, ovarian disorder, pancreatic adenocarcinoma, primitive neuroectodermal tumor, prostate cancer, prostate disorder, renal cell carcinoma, skin disorder, skin neoplasm, squamous cell carcinoma, squamous cell neoplasm, triple-negative breast carcinoma, urinary bladder cancer, urinary bladder disorder, urinary bladder neoplasm, urinary system disorder, uterine disorder | Active, not recruiting | Phase 1 | 2025-11-28 | NCT03983954 | |
| Fulvestrant +/- Akt Inhibition in Advanced Aromatase Inhibitor Resistant Breast Cancer | estrogen-receptor positive breast cancer | Active, not recruiting | Phase 1 / Phase 2 | 2025-11-26 | NCT01992952 | |
| Breast Re-irradiation After Second Ipsilateral Lumpectomy | Neoplasms by Site, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, cancer, estrogen-receptor positive breast cancer, neoplasm, skin disorder | Recruiting | Not applicable | 2025-11-13 | NCT06867484 | |
| FDG PET/CT in Breast Cancer Bone Mets | estrogen-receptor positive breast cancer | Active, not recruiting | Not stated | 2025-09-02 | NCT01996046 | |
| Evaluation of a Novel Technique for the Discovery of New, Tumor-specific Targets for the Deployment of Innovative Immunotherapeutics Against Cancer. | estrogen-receptor positive breast cancer | Enrolling by invitation | Not applicable | 2025-08-29 | NCT06629233 | |
| A Study to See Whether Estrogen Can Slow the Growth of Some ER Positive Breast Cancers | estrogen-receptor positive breast cancer | Active, not recruiting | Phase 2 | 2025-06-26 | NCT02238808 | |
| A Trial of Early Detection of Molecular Relapse With Circulating Tumour DNA Tracking and Treatment With Palbociclib Plus Fulvestrant Versus Standard Endocrine Therapy in Patients With ER Positive HER2 Negative Breast Cancer | estrogen-receptor positive breast cancer | Recruiting | Phase 2 | 2024-12-05 | NCT04985266 | |
| Improvement of Quality of Life Through Supportive Treatments for Hormone Therapy - Related Symptoms in Patients With Early Breast Cancer | Chemically-Induced Disorders, Drug-Related Side Effects and Adverse Reactions, Musculoskeletal Pain, Neoplasms by Site, Neurologic Manifestations, Pain, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, estrogen-receptor positive breast cancer, muscle tissue disorder, musculoskeletal system disorder, neoplasm, skin disorder | Not yet recruiting | Phase 3 | 2024-11-05 | NCT06407401 | |
| Early Changes in Metabolic Health in Breast Cancer Patients Initiating Endocrine Therapy | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, estrogen-receptor positive breast cancer, neoplasm, skin disorder | Not yet recruiting | Not stated | 2024-10-02 | NCT06623903 |